Document And Entity Information
Document And Entity Information - shares | 6 Months Ended | |
Jun. 30, 2016 | Aug. 01, 2016 | |
Document Information [Line Items] | ||
Document Type | 10-Q | |
Amendment Flag | false | |
Document Period End Date | Jun. 30, 2016 | |
Document Fiscal Year Focus | 2,016 | |
Document Fiscal Period Focus | Q2 | |
Entity Registrant Name | Protalix BioTherapeutics, Inc. | |
Entity Central Index Key | 1,006,281 | |
Current Fiscal Year End Date | --12-31 | |
Entity Filer Category | Accelerated Filer | |
Trading Symbol | PLX | |
Entity Common Stock, Shares Outstanding | 99,808,240 |
CONDENSED CONSOLIDATED BALANCE
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands | Jun. 30, 2016 | Dec. 31, 2015 |
CURRENT ASSETS: | ||
Cash and cash equivalents | $ 54,626 | $ 76,374 |
Accounts receivable - Trade | 1,493 | 0 |
Other assets | 5,135 | 1,667 |
Inventories | 6,067 | 5,767 |
Assets of discontinued operations | 324 | 2,073 |
Total current assets | 67,645 | 85,881 |
FUNDS IN RESPECT OF EMPLOYEE RIGHTS UPON RETIREMENT | 1,739 | 1,628 |
PROPERTY AND EQUIPMENT, NET | 9,480 | 9,744 |
Total assets | 78,864 | 97,253 |
Accounts payable and accruals: | ||
Trade | 3,819 | 3,629 |
Other | 6,844 | 5,534 |
Deferred revenues | 504 | 504 |
Liabilities of discontinued operations | 293 | 1,568 |
Total current liabilities | 11,460 | 11,235 |
LONG TERM LIABILITIES: | ||
Convertible notes | 68,017 | 67,796 |
Deferred revenues | 617 | 744 |
Liability for employee rights upon retirement | 2,445 | 2,304 |
Promissory note | 4,301 | 4,301 |
Total long term liabilities | 75,380 | 75,145 |
Total liabilities | 86,840 | 86,380 |
COMMITMENTS | ||
SHAREHOLDERS’ EQUITY (CAPITAL DEFICIENCY) | (7,976) | 10,873 |
Total liabilities and shareholders’ equity (net of capital deficiency) | $ 78,864 | $ 97,253 |
CONDENSED CONSOLIDATED STATEMEN
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | |||
Jun. 30, 2016 | Jun. 30, 2015 | Jun. 30, 2016 | Jun. 30, 2015 | ||
REVENUES | $ 1,769 | $ 1,336 | $ 2,448 | $ 3,028 | |
COST OF REVENUES | (1,675) | (225) | (2,198) | (507) | |
GROSS PROFIT | 94 | 1,111 | 250 | 2,521 | |
RESEARCH AND DEVELOPMENT EXPENSES | [1] | (10,013) | (6,023) | (17,347) | (12,123) |
Less - grants | 2,194 | 1,329 | 3,503 | 2,457 | |
RESEARCH AND DEVELOPMENT EXPENSES, NET | (7,819) | (4,694) | (13,844) | (9,666) | |
SELLING, GENERAL AND ADMINISTRATIVE EXPENSES | [1] | (2,206) | (2,001) | (4,201) | (3,823) |
OPERATING LOSS | (9,931) | (5,584) | (17,795) | (10,968) | |
FINANCIAL EXPENSES | (901) | (642) | (1,805) | (1,799) | |
FINANCIAL INCOME | 96 | 43 | 338 | 71 | |
FINANCIAL EXPENSES - NET | (805) | (599) | (1,467) | (1,728) | |
LOSS FROM CONTINUING OPERATIONS | (10,736) | (6,183) | (19,262) | (12,696) | |
(LOSS) INCOME FROM DISCONTINUED OPERATIONS | (117) | 1,112 | (189) | 1,653 | |
NET LOSS FOR THE PERIOD | $ (10,853) | $ (5,071) | $ (19,451) | $ (11,043) | |
NET LOSS PER SHARE OF COMMON STOCK - BASIC AND DILUTED: | |||||
Loss from continuing operations (in dollars per share) | $ (0.11) | $ (0.06) | $ (0.2) | $ (0.14) | |
Income from discontinued operations (in dollars per share) | 0 | 0.01 | 0 | 0.02 | |
Net loss per share of common stock (in dollars per share) | $ (0.11) | $ (0.05) | $ (0.2) | $ (0.12) | |
WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING LOSS PER SHARE - BASIC AND DILUTED: (in shares) | 99,758,511 | 93,635,213 | 99,737,348 | 93,418,666 | |
[1] | Includes share-based compensation |
CONDENSED CONSOLIDATED STATEME4
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2016 | Jun. 30, 2015 | Jun. 30, 2016 | Jun. 30, 2015 | |
Research and Development Expense [Member] | ||||
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] | ||||
Share-based compensation | $ 128 | $ 283 | $ 366 | $ 409 |
General and Administrative Expense [Member] | ||||
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] | ||||
Share-based compensation | $ 99 | $ 271 | $ 236 | $ 564 |
CONDENSED CONSOLIDATED STATEME5
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (CAPITAL DEFICIENCY) - USD ($) $ in Thousands | Total | Common Stock [Member] | Additional Paid-in Capital [Member] | Accumulated Deficit [Member] | ||
Balance at Dec. 31, 2014 | $ (55,601) | $ 94 | $ 185,633 | $ (241,328) | ||
Balance (in shares) at Dec. 31, 2014 | [1] | 93,603,819 | ||||
Share-based compensation related to stock options | 595 | 595 | ||||
Share-based compensation related to restricted stock award, net of forfeitures | 378 | 378 | ||||
Share-based compensation related to restricted stock award, net of forfeitures (in shares) | [1] | (2,501) | ||||
Exercise of options | 534 | [2] | 534 | |||
Exercise of options (in shares) | [1] | 550,000 | ||||
Net loss from continuing operations | (12,696) | (12,696) | ||||
Net income (loss) from discontinued operations | 1,653 | 1,653 | ||||
Balance at Jun. 30, 2015 | (65,137) | $ 94 | 187,140 | (252,371) | ||
Balance (in shares) at Jun. 30, 2015 | [1] | 94,151,318 | ||||
Balance at Dec. 31, 2015 | 10,873 | $ 100 | 194,064 | (183,291) | ||
Balance (in shares) at Dec. 31, 2015 | [1] | 99,800,397 | ||||
Share-based compensation related to stock options | 534 | 534 | ||||
Share-based compensation related to restricted stock award, net of forfeitures | 68 | 68 | ||||
Share-based compensation related to restricted stock award, net of forfeitures (in shares) | [1] | 7,843 | ||||
Net loss from continuing operations | (19,262) | (19,262) | ||||
Net income (loss) from discontinued operations | (189) | (189) | ||||
Balance at Jun. 30, 2016 | $ (7,976) | $ 100 | $ 194,666 | $ (202,742) | ||
Balance (in shares) at Jun. 30, 2016 | [1] | 99,808,240 | ||||
[1] | Common Stock, $0.001 par value; Authorized as of June 30, 2016 and 2015 - 150,000,000 shares. | |||||
[2] | Represents an amount less than $1. |
CONDENSED CONSOLIDATED STATEME6
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (CAPITAL DEFICIENCY) (Parenthetical) - $ / shares | 6 Months Ended | |
Jun. 30, 2015 | Jun. 30, 2016 | |
Share-based compensation related to restricted stock award, forfeitures, (in shares) | 2,501 | |
Common stock, par value per share | $ 0.001 | |
Common stock, shares authorized | 150,000,000 | 150,000,000 |
CONDENSED CONSOLIDATED STATEME7
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands | 6 Months Ended | |
Jun. 30, 2016 | Jun. 30, 2015 | |
CASH FLOWS FROM OPERATING ACTIVITIES: | ||
Net loss | $ (19,451) | $ (11,043) |
Income (loss) from discontinued operations | (189) | 1,653 |
Loss from continuing operations | (19,262) | (12,696) |
Adjustments required to reconcile net loss to net cash used in operating activities: | ||
Share based compensation | 602 | 973 |
Depreciation | 1,006 | 1,223 |
Financial expenses, net (mainly exchange differences) | (167) | (55) |
Changes in accrued liability for employee rights upon retirement | 107 | (37) |
Loss (gain) on amounts funded in respect of employee rights upon retirement | (3) | 23 |
Amortization of debt issuance costs and debt discount | 221 | 221 |
Changes in operating assets and liabilities: | ||
Increase (decrease) in deferred revenues (including non-current portion) | (127) | 121 |
(Increase) decrease in accounts receivable and other assets | (4,952) | 11 |
(Increase) decrease in inventories | (300) | 335 |
Increase (decrease) in accounts payable and accruals (including long term ) | 1,273 | (640) |
Net cash used in continuing operations | (21,602) | (10,521) |
Net cash provided by (used in) discontinued operations | 285 | (1,246) |
Net cash used in operating activities | (21,317) | (11,767) |
CASH FLOWS FROM INVESTING ACTIVITIES: | ||
Purchase of property and equipment | (575) | (332) |
Amounts funded in respect of employee rights upon retirement, net | (84) | (15) |
Net cash used in investing activities | (659) | (347) |
CASH FLOWS FROM FINANCING ACTIVITIES: | ||
Exercise of options | 0 | 534 |
Net cash provided by financing activities | 0 | 534 |
EFFECT OF EXCHANGE RATE CHANGES ON CASH | 228 | 51 |
NET DECREASE IN CASH AND CASH EQUIVALENTS | (21,748) | (11,529) |
BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD | 76,374 | 54,767 |
BALANCE OF CASH AND CASH EQUIVALENTS AT END OF PERIOD | 54,626 | 43,238 |
SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS: | ||
Purchase of property and equipment | 656 | 121 |
SUPPLEMENTARY DISCLOSURE ON CASH FLOWS | ||
Interest paid | $ 1,553 | $ 1,553 |
SIGNIFICANT ACCOUNTING POLICIES
SIGNIFICANT ACCOUNTING POLICIES | 6 Months Ended |
Jun. 30, 2016 | |
SIGNIFICANT ACCOUNTING POLICIES [Abstract] | |
SIGNIFICANT ACCOUNTING POLICIES | NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES General Protalix BioTherapeutics, Inc. (collectively with its subsidiaries, the “Company”), and its wholly-owned subsidiaries, Protalix Ltd. and Protalix B.V. (“Subsidiaries”), are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company’s proprietary ProCellEx ® TM ® The Company’s product pipeline currently includes, among other candidates: (1) PRX-102, or alpha-GAL-A, a therapeutic protein candidate for the treatment of Fabry disease, a rare, genetic lysosomal disorder; (2) PRX-110, a proprietary plant cell recombinant human Deoxyribonuclease 1, or DNase, under development for the treatment of cystic fibrosis, to be administered by inhalation; and (3) PRX-106, the Company’s oral antiTNF product candidate which is being developed as an orally-delivered anti inflammatory treatment using plant cells as a natural capsule for the expressed protein. Obtaining marketing approval with respect to any product candidate in any country is directly dependent on the Company’s ability to comply with all regulatory requirements to obtain such approvals. The Company cannot reasonably predict the outcome of these activities. Since its approval by the U.S. Food and Drug Administration 36.0 60 On June 18, 2013, the Company entered into a Supply and Technology Transfer Agreement (the “Brazil Agreement”) with Fundação Oswaldo Cruz (“Fiocruz”), an arm of the Brazilian Ministry of Health for taliglucerase alfa. Fiocruz’s purchases of Uplyso to date have been significantly below certain agreed upon purchase milestones and, accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding the low purchase amounts, the Company is, at this time, continuing to supply Uplyso to Fiocruz under the Brazil Agreement, and patients continue to be treated with Uplyso in Brazil. The Company is discussing with Fiocruz potential actions that Fiocruz may take to comply with its purchase obligations and, based on such discussions, the Company will determine what it believes to be the course of action that is in the best interest of the Company. Based on its current cash resources and commitments, the Company believes it will be able to maintain its current planned development activities and the corresponding level of expenditures for at least 12 months, although no assurance can be given that it will not need additional funds prior to such time. If there are unexpected increases in general and administrative expenses or research and development expenses, the Company may need to seek additional financing. Basis of presentation The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature) considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results for the interim period are not necessarily indicative of the results that may be expected for the full year. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form 10-K for the year ended December 31, 2015, filed by the Company with the U.S. Securities and Exchange Commission. The comparative balance sheet at December 31, 2015 has been derived from the audited financial statements at that date. c. Net earnings (loss) per share Basic and diluted loss per share (“LPS”) are computed by dividing net loss by the weighted average number of shares of the Company’s Common Stock, par value $ 0.001 Diluted LPS is calculated in continuing operations. The calculation of diluted LPS does not include 19,780,594 19,617,149 20,167,947 19,586,488 |
INVENTORIES
INVENTORIES | 6 Months Ended |
Jun. 30, 2016 | |
INVENTORIES [Abstract] | |
INVENTORIES | NOTE 2 - INVENTORIES June 30, December 31, 2016 2015 (U.S. dollars in thousands) Raw materials $ 2,027 $ 1,180 Work in progress 219 Finished goods 3,821 4,587 Total inventory $ 6,067 $ 5,767 |
FAIR VALUE MEASUREMENT
FAIR VALUE MEASUREMENT | 6 Months Ended |
Jun. 30, 2016 | |
FAIR VALUE MEASUREMENT [Abstract] | |
FAIR VALUE MEASUREMENT | NOTE 3 FAIR VALUE MEASUREMENT The Company measures fair value and discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received from the sale of an asset, or paid to transfer a liability, in an orderly transaction between market participants at the measurement date. The accounting standard establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below: Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs. Level 2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data. Level 3: In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value. The fair value of the financial instruments included in the working capital of the Company is usually identical or close to their carrying value. The fair value of the convertible notes as of June 30, 2016 is approximately $ 45.9 |
DISCONTINUED OPERATIONS
DISCONTINUED OPERATIONS | 6 Months Ended |
Jun. 30, 2016 | |
Discontinued Operations and Disposal Groups [Abstract] | |
DISCONTINUED OPERATIONS | NOTE 4 DISCONTINUED OPERATIONS The Company accounted for the termination of the Pfizer Agreement and the sale of the license as discontinued operations, in accordance with Accounting Standards Update (ASU) No. 2014-08. The following assets and liabilities associated with the Company’s discontinued operations, have been segregated and classified as assets and liabilities of discontinued operations, as appropriate, in the consolidated balance sheets as of December 31, 2015 and June 30, 2016, respectively: June 30, 2016 December 31, 2015 (U.S. dollars in thousands) CURRENT ASSETS: Accounts receivable - Trade $ 324 $ 1,993 Inventories 80 Total current assets of discontinued operations 324 2,073 CURRENT LIABILITIES: Accounts payable and accruals: Other 293 1,568 Total current liabilities of discontinued operations 293 1,568 The following summarizes financial information related to the Company’s discontinued operations in the Company’s consolidated statements of operations for the three months and six months ended June 30, 2015 and June 30, 2016: Six Months Ended Three Months Ended June 30, 2016 June 30, 2015 June 30, 2016 June 30, 2015 REVENUES $ 209 $ 5,146 $ $ 2,446 COMPANY’S SHARE IN COLLABORATION AGREEMENT 1,539 834 COST OF REVENUES (373) (3,932) (167) (1,814) GROSS PROFIT (LOSS) (164) 2,753 (167) 1,466 RESEARCH AND DEVELOPMENT EXPENSES (1,110) (448) Less reimbursements 192 185 RESEARCH AND DEVELOPMENT EXPENSES, NET (918) (263) SELLING, GENERAL AND ADMINISTRATIVE EXPENSES (25) (182) 50 (91) NET Income (LOSS) FOR THE PERIOD FROM DISCONTINUED OPERATIONS (189) 1,653 (117) 1,112 |
SIGNIFICANT ACCOUNTING POLICI12
SIGNIFICANT ACCOUNTING POLICIES (Policies) | 6 Months Ended |
Jun. 30, 2016 | |
SIGNIFICANT ACCOUNTING POLICIES [Abstract] | |
General | General Protalix BioTherapeutics, Inc. (collectively with its subsidiaries, the “Company”), and its wholly-owned subsidiaries, Protalix Ltd. and Protalix B.V. (“Subsidiaries”), are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company’s proprietary ProCellEx ® TM ® The Company’s product pipeline currently includes, among other candidates: (1) PRX-102, or alpha-GAL-A, a therapeutic protein candidate for the treatment of Fabry disease, a rare, genetic lysosomal disorder; (2) PRX-110, a proprietary plant cell recombinant human Deoxyribonuclease 1, or DNase, under development for the treatment of cystic fibrosis, to be administered by inhalation; and (3) PRX-106, the Company’s oral antiTNF product candidate which is being developed as an orally-delivered anti inflammatory treatment using plant cells as a natural capsule for the expressed protein. Obtaining marketing approval with respect to any product candidate in any country is directly dependent on the Company’s ability to comply with all regulatory requirements to obtain such approvals. The Company cannot reasonably predict the outcome of these activities. Since its approval by the U.S. Food and Drug Administration 36.0 60 On June 18, 2013, the Company entered into a Supply and Technology Transfer Agreement (the “Brazil Agreement”) with Fundação Oswaldo Cruz (“Fiocruz”), an arm of the Brazilian Ministry of Health for taliglucerase alfa. Fiocruz’s purchases of Uplyso to date have been significantly below certain agreed upon purchase milestones and, accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding the low purchase amounts, the Company is, at this time, continuing to supply Uplyso to Fiocruz under the Brazil Agreement, and patients continue to be treated with Uplyso in Brazil. The Company is discussing with Fiocruz potential actions that Fiocruz may take to comply with its purchase obligations and, based on such discussions, the Company will determine what it believes to be the course of action that is in the best interest of the Company. Based on its current cash resources and commitments, the Company believes it will be able to maintain its current planned development activities and the corresponding level of expenditures for at least 12 months, although no assurance can be given that it will not need additional funds prior to such time. If there are unexpected increases in general and administrative expenses or research and development expenses, the Company may need to seek additional financing. |
Basis of presentation | Basis of presentation The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature) considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results for the interim period are not necessarily indicative of the results that may be expected for the full year. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form 10-K for the year ended December 31, 2015, filed by the Company with the U.S. Securities and Exchange Commission. The comparative balance sheet at December 31, 2015 has been derived from the audited financial statements at that date. |
Net earnings (loss) per share | c. Net earnings (loss) per share Basic and diluted loss per share (“LPS”) are computed by dividing net loss by the weighted average number of shares of the Company’s Common Stock, par value $ 0.001 Diluted LPS is calculated in continuing operations. The calculation of diluted LPS does not include 19,780,594 19,617,149 20,167,947 19,586,488 |
INVENTORIES (Tables)
INVENTORIES (Tables) | 6 Months Ended |
Jun. 30, 2016 | |
INVENTORIES [Abstract] | |
Schedule of Inventory | Inventory at June 30, 2016 and December 31, 2015 consisted of the following: June 30, December 31, 2016 2015 (U.S. dollars in thousands) Raw materials $ 2,027 $ 1,180 Work in progress 219 Finished goods 3,821 4,587 Total inventory $ 6,067 $ 5,767 |
DISCONTINUED OPERATIONS (Tables
DISCONTINUED OPERATIONS (Tables) | 6 Months Ended |
Jun. 30, 2016 | |
Discontinued Operations and Disposal Groups [Abstract] | |
Schedule of Discontinued Operations | The Company accounted for the termination of the Pfizer Agreement and the sale of the license as discontinued operations, in accordance with Accounting Standards Update (ASU) No. 2014-08. The following assets and liabilities associated with the Company’s discontinued operations, have been segregated and classified as assets and liabilities of discontinued operations, as appropriate, in the consolidated balance sheets as of December 31, 2015 and June 30, 2016, respectively: June 30, 2016 December 31, 2015 (U.S. dollars in thousands) CURRENT ASSETS: Accounts receivable - Trade $ 324 $ 1,993 Inventories 80 Total current assets of discontinued operations 324 2,073 CURRENT LIABILITIES: Accounts payable and accruals: Other 293 1,568 Total current liabilities of discontinued operations 293 1,568 The following summarizes financial information related to the Company’s discontinued operations in the Company’s consolidated statements of operations for the three months and six months ended June 30, 2015 and June 30, 2016: Six Months Ended Three Months Ended June 30, 2016 June 30, 2015 June 30, 2016 June 30, 2015 REVENUES $ 209 $ 5,146 $ $ 2,446 COMPANY’S SHARE IN COLLABORATION AGREEMENT 1,539 834 COST OF REVENUES (373) (3,932) (167) (1,814) GROSS PROFIT (LOSS) (164) 2,753 (167) 1,466 RESEARCH AND DEVELOPMENT EXPENSES (1,110) (448) Less reimbursements 192 185 RESEARCH AND DEVELOPMENT EXPENSES, NET (918) (263) SELLING, GENERAL AND ADMINISTRATIVE EXPENSES (25) (182) 50 (91) NET Income (LOSS) FOR THE PERIOD FROM DISCONTINUED OPERATIONS (189) 1,653 (117) 1,112 |
SIGNIFICANT ACCOUNTING POLICI15
SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details) - USD ($) $ / shares in Units, $ in Millions | 3 Months Ended | 6 Months Ended | |||
Jun. 30, 2016 | Jun. 30, 2015 | Jun. 30, 2016 | Jun. 30, 2015 | Oct. 31, 2015 | |
Significant Accounting Policies [Line Items] | |||||
Common Stock, Par or Stated Value Per Share | $ 0.001 | $ 0.001 | |||
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | 19,586,488 | 20,167,947 | 19,617,149 | 19,780,594 | |
Payment Received Under License And Supply Agreement | $ 36 | ||||
Pfizer Agreement [Member] | Protalix Bio Therapeutics Incorporation [Member] | |||||
Significant Accounting Policies [Line Items] | |||||
Collaborative Arrangement Revenues and Expenses Sharing Percentage | 40.00% | ||||
Pfizer Agreement [Member] | Pfizer Incorporation [Member] | |||||
Significant Accounting Policies [Line Items] | |||||
Collaborative Arrangement Revenues and Expenses Sharing Percentage | 60.00% | ||||
Amended Pfizer Agreement [Member] | Brazil [Member] | Protalix Bio Therapeutics Incorporation [Member] | |||||
Significant Accounting Policies [Line Items] | |||||
Collaborative Arrangement Revenues and Expenses Sharing Percentage | 100.00% |
INVENTORIES (Details)
INVENTORIES (Details) - USD ($) $ in Thousands | Jun. 30, 2016 | Dec. 31, 2015 |
Raw materials | $ 2,027 | $ 1,180 |
Work in progress | 219 | |
Finished goods | 3,821 | 4,587 |
Total inventory | $ 6,067 | $ 5,767 |
FAIR VALUE MEASUREMENT (Narrati
FAIR VALUE MEASUREMENT (Narrative) (Details) $ in Millions | Jun. 30, 2016USD ($) |
Convertible Debt, Fair Value Disclosures | $ 45.9 |
DISCONTINUED OPERATIONS (Balanc
DISCONTINUED OPERATIONS (Balance Sheets) (Details) - USD ($) $ in Thousands | Jun. 30, 2016 | Dec. 31, 2015 |
CURRENT ASSETS: | ||
Accounts receivable - Trade | $ 324 | $ 1,993 |
Inventories | 80 | |
Total current assets of discontinued operations | 324 | 2,073 |
Accounts payable and accruals: | ||
Other | 293 | 1,568 |
Total current liabilities of discontinued operations | $ 293 | $ 1,568 |
DISCONTINUED OPERATIONS (Operat
DISCONTINUED OPERATIONS (Operations) (Details) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2016 | Jun. 30, 2015 | Jun. 30, 2016 | Jun. 30, 2015 | |
REVENUES | $ 0 | $ 2,446 | $ 209 | $ 5,146 |
COMPANY’S SHARE IN COLLABORATION AGREEMENT | 834 | 1,539 | ||
COST OF REVENUES | (167) | (1,814) | (373) | (3,932) |
GROSS PROFIT (LOSS) | (167) | 1,466 | (164) | 2,753 |
RESEARCH AND DEVELOPMENT EXPENSES | (448) | (1,110) | ||
Less - reimbursements | 185 | 192 | ||
RESEARCH AND DEVELOPMENT EXPENSES, NET | (263) | (918) | ||
SELLING, GENERAL AND ADMINISTRATIVE EXPENSES | 50 | (91) | (25) | (182) |
NET Income (LOSS) FOR THE PERIOD FROM DISCONTINUED OPERATIONS | $ (117) | $ 1,112 | $ (189) | $ 1,653 |